期刊
JOURNAL OF INFECTIOUS DISEASES
卷 208, 期 8, 页码 1342-1348出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jit327
关键词
Cryptosporidium parvum; cryptosporidiosis; Calcium-dependant Protein kinase; CpCDPK-1; bumped kinase inhibitor; antiparasitic
资金
- National Institutes of Health [R01AI089441, R01GM086858, KL2TR000072]
- University of Washington Plein Endowment for Geriatric Pharmacy Research
Cryptosporidium parasites infect intestinal cells, causing cryptosporidiosis. Despite its high morbidity and association with stunting in the developing world, current therapies for cryptosporidiosis have limited efficacy. Calcium-dependent protein kinases (CDPKs) are essential enzymes in the biology of protozoan parasites. CDPK1 was cloned from the genome of Cryptosporidium parvum, and potent and specific inhibitors have been developed based on structural studies. In this study, we evaluated the anti-Cryptosporidium activity of a novel CDPK1 inhibitor, 1294, and demonstrated that 1294 significantly reduces parasite infection in vitro, with a half maximal effective concentration of 100 nM. Pharmacokinetic studies revealed that 1294 is well absorbed, with a half-life supporting daily administration. Oral therapy with 1294 eliminated Cryptosporidium parasites from 6 of 7 infected severe combined immunodeficiency-beige mice, and the parasites did not recur in these immunosuppressed mice. Mice treated with 1294 had less epithelial damage, corresponding to less apoptosis. Thus, 1294 is an important lead for the development of drugs for treatment of cryptosporidiosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据